TG-100801

N/A

Report date: 2022/10/14 20:00:43
NME

Base Information

Drug NameTG-100801
Drug Alias NameTG-100801
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsEphrin type-B receptor 4 antagonistsVascular endothelial growth factor receptor antagonists +[4] 
TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptorEphrin type-B receptor 4 +[4] 
Therapy Area/IndicationsChoroidal NeovascularizationMacular DegenerationDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTargegen Inc
Active IndicationsN/A
Inactive IndicationsChoroidal NeovascularizationMacular DegenerationDiabetic Retinopathy

Other Information

ATC CodeN/A
Related LinksDrugBank